Back

Expression of Toll like Receptor 4 in the ductal epithelial cells of the Breast tumor microenvironment is correlated with the invasiveness of the tumor

MOIRANGTHEM, A.; MUKHERJEE, M.; BANDYOPADHYAY, B.; BONDHOPADHYAY, A.; MUKHERJEE, N.; KONAR, K.; Das, T.; DUTTA, P.; BASU, A.

2020-03-16 cancer biology
10.1101/2020.03.15.993014 bioRxiv
Show abstract

Toll like receptors are expressed by variety of cells, mainly immune cells and also found to have role in the tumor microenvironment. Among them, Toll like receptors-4 is found to modulate tumor progression. But definitive action of TLR4 in tumor progression is not well understood. In the present study, in breast tumor samples, expression of TLR4 was studied by immunohistochemistry method while MMP2 and MMP9 expression were studied by gelatin zymography. Kaplan Meier plotter was used to test survivability. Breast cancer cells - MCF7, MDA MB 231, T47D were studied in the presence of TLR4 lignd LPS, with the help of MTT assay, BrdU incorporation assay, scratch wound healing assay and invasion assay. Activation of TLR4 in MCF7 which is TP53 wild type has no significant effect in proliferative rate, adhesiveness and invasiveness. While in MDA-MB-231 and T47D which are TP53 mutant, there were a significant increase in adhesiveness and migratory ability, observed., TLR4 had been expressed in breast tumor of invasive ductal carcinoma (IDC) and was found to be significantly correlated with lymph node involvement. Kaplan Meier plotter analysis revealed that high TLR4 expression might serve as an immune-protectant in invading cancer cells of TP53 wild state. It has been revealed that activation of TLR4 in breast cancer cells leads to higher expression of EMT related genes along with matrix metalloproteinases helping in migration and invasion of cells. Kaplan Meier plotter analysis revealed that TP53 wild status of the patient along with high TLR4 expression has a good overall survival of the patients.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 9%
18.6%
2
Gene Reports
13 papers in training set
Top 0.1%
12.4%
3
Scientific Reports
3102 papers in training set
Top 8%
9.2%
4
Cancers
200 papers in training set
Top 1%
4.2%
5
Frontiers in Oncology
95 papers in training set
Top 1.0%
4.0%
6
PeerJ
261 papers in training set
Top 2%
4.0%
50% of probability mass above
7
BMC Cancer
52 papers in training set
Top 0.7%
3.6%
8
Bioscience Reports
25 papers in training set
Top 0.3%
2.7%
9
F1000Research
79 papers in training set
Top 0.8%
2.6%
10
Heliyon
146 papers in training set
Top 0.7%
2.6%
11
Frontiers in Immunology
586 papers in training set
Top 3%
2.6%
12
International Journal of Molecular Sciences
453 papers in training set
Top 5%
2.1%
13
BioMed Research International
25 papers in training set
Top 1%
1.8%
14
Biomedicines
66 papers in training set
Top 0.9%
1.7%
15
Molecular Biology Reports
19 papers in training set
Top 0.2%
1.7%
16
Biochemistry and Biophysics Reports
28 papers in training set
Top 0.8%
1.3%
17
Diagnostics
48 papers in training set
Top 1%
1.2%
18
Informatics in Medicine Unlocked
21 papers in training set
Top 0.8%
1.0%
19
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 7%
1.0%
20
Journal of Clinical Medicine
91 papers in training set
Top 5%
0.9%
21
Journal of Personalized Medicine
28 papers in training set
Top 0.9%
0.9%
22
Archives of Clinical and Biomedical Research
28 papers in training set
Top 2%
0.8%
23
Life Sciences
25 papers in training set
Top 1%
0.7%
24
Frontiers in Physiology
93 papers in training set
Top 6%
0.7%
25
Gene
41 papers in training set
Top 3%
0.6%
26
Frontiers in Pharmacology
100 papers in training set
Top 5%
0.6%
27
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 1%
0.6%